| Kelsey Henry, | |
|
3807 Fish Pond Ln, Glen Allen, VA 23060-5947 | |
| (800) 330-7711 | |
| Not Available |
| Full Name | Kelsey Henry |
|---|---|
| Gender | Female |
| Speciality | Occupational Therapist |
| Location | 3807 Fish Pond Ln, Glen Allen, Virginia |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1811370141 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225X00000X | Occupational Therapist | 0119006642 (Virginia) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Kelsey Henry, 3807 Fish Pond Ln, Glen Allen, VA 23060-5947 Ph: () - | Kelsey Henry, 3807 Fish Pond Ln, Glen Allen, VA 23060-5947 Ph: (800) 330-7711 |
News Archive
Baxter International Inc. and Nycomed today announced the U.S. Food and Drug Administration (FDA) approval of TachoSil (Absorbable Fibrin Sealant Patch) for use as an adjunct to hemostasis in cardiovascular surgery. TachoSil is the first and only adjunctive hemostatic agent available in the U.S. that combines a collagen patch with a coating of human coagulation factors.
Patient Safety Technologies, Inc. today announced the closing of a $5 million senior secured term loan. At close, $4 million of the term loan was funded. The Company has the ability to draw an incremental $1 million under the term loan, subject to certain conditions. The five-year term loan matures in 2018 and bears interest at 13% per annum.
Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced that it has submitted a Phase IIb protocol to the U.S. Food and Drug Administration (FDA) for the clinical study of Serdaxin for the treatment of major depressive disorder (MDD).
Researchers from the Albert Einstein College of Medicine and The University of Pittsburgh have developed an onsite method to quickly diagnose tuberculosis (TB) and expose the deadly drug-resistant strains that can mingle undetected with treatable TB strains.
caprotec bioanalytics GmbH announced today the discovery of previously unknown specific drug-protein interactions for several anti-cancer drugs and the identification of potential novel co-targets of the drug molecules through the use of company's CCMS technology.
› Verified 2 days ago
Christian Taylor Stallings, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 10124 W Broad St Ste P, Glen Allen, VA 23060 Phone: 804-273-6656 | |
Andrea Lewis, Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 4900 Twin Hickory Lake Dr, Glen Allen, VA 23059 Phone: 804-360-4700 | |
Mrs. Joyce Irene Koontz, OT Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 10124 W Broad St Ste K, Glen Allen, VA 23060 Phone: 804-273-6656 | |
Allison Davis, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 4413 Cox Rd, Glen Allen, VA 23060 Phone: 804-386-0485 | |
Stacie Lynn Baldwin, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 12101 Liesfeld Farm Dr, Glen Allen, VA 23059 Phone: 804-364-0055 | |
Linda Layne Lindsey-hoy, OT Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 10299 Woodman Rd, Glen Allen, VA 23060 Phone: 804-727-8500 Fax: 804-727-8580 | |
Caitlin Marie Underwood, MSOT, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 4413 Cox Rd, Glen Allen, VA 23060 Phone: 803-386-0485 |